Although anti-CX3CL1 mAb alone did not exert therapeutic effects against lung fibrosis, its combination therapy with anti-fibrotic drugs, such as nintedanib or pirfenidone, may be expected to have a therapeutic effect on ILD. Here, CX3CL1 is linked to interstitial lung disease.